|Home- - -History-- -Bibliography- -Pregnancy Timeline- --Prescription Drugs in Pregnancy- -- Pregnancy Calculator- --Female Reproductive System- News Alerts -Contact|
Click weeks 0 - 40 and follow fetal growth
Catching Autism At The 1-year Well-Baby Check-Up
A New Wrinkle In The Genetic Code
Tired Neurons Nod Off in Sleep-Deprived Rats
Obese Adolescents Lacking Vitamin D
April 27, 2011--------News Archive
Men and Women Respond Differently to PTSD
Motor Protein May Offer Promise In Ovarian Cancer
Best Treatment For Gestational Tumors
Frog Embryos Teach Us About Heart Development
Brain Cells Offer Insight on How Cancer Spreads
Georgia Health Sciences University researchers are looking at blood levels of interleukin-1 receptor antagonist, or IL-1ra, in children being closely followed because their genes put them at risk for type 1 diabetes.
They also are looking at diabetic mice missing IL-1ra to see how the protein deficiency affects immune function and destruction of insulin-producing islet beta cells. “We want to know if we can use IL-1ra levels to identify children who will soon develop the disease, then use IL-1 inhibitors to prevent it,” said Dr. Sharad Purohit, biochemist in the GHSU Center for Biotechnology and Genomic Medicine.
IL-1ra helps reduce inflammation and Purohit’s preliminary evidence suggests that low levels predict inflammation is increasing and the immune system is going to attack insulin-producing cells.
A three-year, $500,000 grant from the Juvenile Diabetes Research Foundation will help him explore the hypothesis in the blood of about 2,500 children as well as the diabetic mice.
Il-1 inhibitors already are used to treat rheumatoid arthritis, where inflammation destroys joints. Clinical trials are underway in type 1 diabetes and to see if an inhibitor can halt the islet cell destruction that occurs in type 1 diabetes as well.
While acknowledging the inhibitor may improve type 1diabetes outcome, GHSU scientists want to know if it can also be used preventively, said Dr. Jin-Xiong She, Director of the Center for Biotechnology and Genomic Medicine.
IL-1ra competes with its counterpart IL-1beta for the IL-1 receptor. In type 1 diabetes, inflammation-promoting IL-1beta appears to be winning. “It’s a balance; it’s a competition,” She said. “There is always a balance between beta cell production and destruction and any process that can change the balance can push you to disease or help you recover from it. In this case, we believe that knowing the balance is off can actually help prevent disease.”
Type 1 diabetes typically presents by puberty, as the body’s immune system inexplicably turns against the pancreas’ insulin-producing cells. By the time the first symptoms occur, such as increased appetite in the face of significant weight loss, as many as 90 percent of the beta cells may be destroyed, leaving a child facing a lifetime of insulin dependency and often complications such as cardiovascular damage and vision loss. Much like the lifestyle-related type 2 diabetes, the incidence of type 1 is increasing.
The recent Juvenile Diabetes Research Foundation award is Purohit’s fourth. He received postdoctoral and senior postdoctoral fellowship awards as well as a transition award when he moved to faculty status in 2009. “This really shows he is on the right track to be a successful investigator,” She said.
Purohit has worked for more than a decade with She, a principal investigator on international studies screening thousands of newborns for high-risk genes then following them for years to help determine how genetics and environment converge to cause type 1 diabetes. She, a Georgia Research Alliance Eminent Scholar in Genomic Medicine, also is helping identify high-risk genes.